Digital Pathology Association Acknowledges Collaborative Efforts with FDA for Whole Slide Imaging

The Digital Pathology Association (DPA) recently announced its suggestion that digital pathology manufacturers currently interested in marketing Whole Slide Imaging (WSI) devices for primary diagnosis in the United States submit de novo applications to the Food and Drug Administration (FDA) based on clarity and guidance provided to the DPA from the FDA.

Click here to read the press release in full.

Published in: Press Releases  on Thursday 18th of February 2016